Agendia has announced it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, which will help scientists quickly and efficiently test new drugs in over 20 research sites.
Results from the unprecedented large-scale scientific collaboration will be made broadly available to the cancer research and development community to encourage this integrated approach to improved clinical trial success.
Agendia chief executive officer Bernhard Sixt said that cancer tumour profiling in the neoadjuvant setting is critical to the success of the I-SPY 2 trial.
"Agendia's MammaPrint test has proven value for breast cancer recurrence in the neoadjuvant and adjuvant settings," Sixt said.
"Agendia's TargetPrint provides objective, quantitative information about the expression of ER, PR and Her-2neu, while our DiscoverPrint measures the expression of the whole genome. In concert they will form an integral part of the clinically relevant discoveries the consortium aims to make."
The I-SPY trial is an initiative of the Biomarkers Consortium, a unique public-private partnership that includes the Food and Drug Administration, the National Institutes of Health, and major pharmaceutical companies, led by the Foundation for the National Institutes of Health.